Argenx’s Vvygart Fails In Thyroid Eye Disease, Denting Expansion Plans
The rare disease blockbuster has stumbled in a key Phase III study, although Argenx still has plenty of other pipeline opportunities.
Scrip - December 15, 2025

Sandoz Asserts ‘Biosimilars Leadership’ As It Completes Just-Evotec Acquisition
Sandoz said it was “asserting biosimilars leadership” as it announced the completion of a deal to acquire Just-Evotec Biologics’s Toulouse development and manufacturing site as well as an indefinite licence to the firm’s continuous manufacturing technology.
Generics Bulletin - December 15, 2025

Hikma Signals Reset With Abrupt CEO Change As Injectables Margins Slide
Hikma has initiated a leadership transition, with CEO Riad Mishlawi stepping down after just two years in the role, as margin pressure in its core Injectables business and operational delays weigh on performance.
Generics Bulletin - December 15, 2025

Selective Risk Taking: Cell And Gene Therapy’s Phoenix Moment
Investors and analysts say cell and gene therapy is entering a disciplined “phoenix” phase, with selective risk taking, AI enabled platforms and new pricing models redefining how one time cures attract capital.
In Vivo - December 15, 2025

Pipeline Watch: Two Approvals & Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 15, 2025

Sobi’s Arthrosi Buyout Gives Its Gout Pipeline More Breadth
Through its buyout of San Diego-based startup Arthrosi, Sobi gains the URAT1 inhibitor pozdeutinurad (AR882) for gout, which is an existing area of focus for the Swedish firm.
Scrip - December 15, 2025

Teva Caves In Under FTC Pressure And Orders The Removal Of Improper Inhaler Patent Listings
After multiple warning letter campaigns, the US FTC has claimed a win as Teva’s request to remove hundreds of Orange Book patent listings will pave a generic competition path for more than 30 products.
Generics Bulletin - December 15, 2025

Deals In Depth: November 2025
Four $1bn+ alliances were penned in November, and three exceeded $2bn. In the top alliance by deal value, Valo Health entered into a potential $3bn collaboration with Merck KGaA to advance therapeutic discovery in Parkinson’s disease and related disorders.
In Vivo - December 15, 2025

Biogen Doubles Down On Immunology As Lupus Programs Near Readouts
With two late-stage lupus assets finishing recruitment and a newly acquired nephrology franchise running three concurrent Phase III programs, Biogen is making its most significant commitment yet to immunology beyond its legacy MS business.
In Vivo - December 15, 2025

All Change For Notified Bodies: Moving Towards A More Highly Regulated Future
Just ahead of the European Commission publishing its proposed revisions of the Medical Device and IVD Regulations, it has released an equally important document on the future of notified body operations in the bloc.
Medtech Insight - December 15, 2025

‘Affordably’ Priced Ozempic In India: Can It Sustain Momentum Post LOE?
Ozempic debuts in India, priced in the ‘affordable zone’ for the country's population, with Novo Nordisk hoping the blockbuster drug can hold its own post impending loss of exclusivity in the country next year.
Scrip - December 15, 2025

No Sale For Supplement Direct Sellers’ Ad Claims In Industry Self-Regulation Group’s Reviews
Urban Retreat didn’t cooperate with Direct Selling Self-Regulatory Council’s review or “indicate any intent to comply with” recommendations to discontinue claims for its Balance Capsules. LoveBiome responded sufficiently to merit a DSSRC recommendation to pull three health claims.
HBW Insight - December 15, 2025

Colorado EPR Program Countdown Begins After State Approves Final Plan
The Colorado Department of Public Health and Environment approved Circular Action Alliance’s final plan for the state’s Extended Producer Responsibility program on Dec. 9.
HBW Insight - December 15, 2025

Quick Listen: Scrip’s Five Must-Know Things
This week, a focus on key results from the American Society of Hematology meeting: Jaypirca headed for the front line; Kite’s Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia’s early in vivo CAR-T data; and Novartis’s ianalumab’s potential in ITP.
Scrip - December 15, 2025